Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039985181> ?p ?o ?g. }
- W2039985181 endingPage "493" @default.
- W2039985181 startingPage "486" @default.
- W2039985181 abstract "Background Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease. We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade). Design Randomized open controlled crossover study. Setting & Participants 18 whites (7 women, 11 men) from the Outpatient Department of Nephrology with chronic nondiabetic proteinuric kidney diseases, mean age 42.4 ± 1.9 years (SEM). Interventions In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg. Participants were then randomly assigned to 2 treatment sequences, either the addition of spironolactone (25 mg) (triple RAAS blockade) through 8 weeks followed by double RAAS blockade through 8 weeks (sequence 1) or double RAAS blockade followed by triple RAAS blockade (sequence 2). Main Outcome Measures 24-hour urine protein excretion (primary end point) and markers of tubular injury and fibrosis (secondary end points). Analysis was performed using analysis of variance for repeated measurements. Results At baseline, mean serum creatinine level was 1.16 ± 0.09 mg/dL (103 ± 8 μmol/L), estimated glomerular filtration rate was 107.8 mL/min (95% confidence interval, 93 to 140.9 [1.8 mL/s; 95% confidence interval, 1.55 to 2.35; Cockcroft-Gault formula), and 24-hour mean proteinuria was 0.97 ± 0.18 g. Mean urine protein excretion was 0.7 g/24 h (95% confidence interval, 0.48 to 0.92) less after triple RAAS blockade than after double RAAS blockade (P = 0.01), without change in blood pressure. Urine excretion of N-acetyl-β-d-glucosaminidase (P = 0.02) and amino-terminal propeptide of type III procollagen (P = 0.05) also significantly decreased. Potassium levels increased significantly after triple therapy (P = 0.02). However, no patient was withdrawn because of adverse effects. Limitations Absence of blinding, small sample size, short treatment period, absence of histological assessment. Conclusions Administration of an aldosterone receptor antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease. Additional studies are necessary to confirm this result. Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease. We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade). Randomized open controlled crossover study. 18 whites (7 women, 11 men) from the Outpatient Department of Nephrology with chronic nondiabetic proteinuric kidney diseases, mean age 42.4 ± 1.9 years (SEM). In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg. Participants were then randomly assigned to 2 treatment sequences, either the addition of spironolactone (25 mg) (triple RAAS blockade) through 8 weeks followed by double RAAS blockade through 8 weeks (sequence 1) or double RAAS blockade followed by triple RAAS blockade (sequence 2). 24-hour urine protein excretion (primary end point) and markers of tubular injury and fibrosis (secondary end points). Analysis was performed using analysis of variance for repeated measurements. At baseline, mean serum creatinine level was 1.16 ± 0.09 mg/dL (103 ± 8 μmol/L), estimated glomerular filtration rate was 107.8 mL/min (95% confidence interval, 93 to 140.9 [1.8 mL/s; 95% confidence interval, 1.55 to 2.35; Cockcroft-Gault formula), and 24-hour mean proteinuria was 0.97 ± 0.18 g. Mean urine protein excretion was 0.7 g/24 h (95% confidence interval, 0.48 to 0.92) less after triple RAAS blockade than after double RAAS blockade (P = 0.01), without change in blood pressure. Urine excretion of N-acetyl-β-d-glucosaminidase (P = 0.02) and amino-terminal propeptide of type III procollagen (P = 0.05) also significantly decreased. Potassium levels increased significantly after triple therapy (P = 0.02). However, no patient was withdrawn because of adverse effects. Absence of blinding, small sample size, short treatment period, absence of histological assessment. Administration of an aldosterone receptor antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease. Additional studies are necessary to confirm this result." @default.
- W2039985181 created "2016-06-24" @default.
- W2039985181 creator A5018798170 @default.
- W2039985181 creator A5026517026 @default.
- W2039985181 creator A5032030602 @default.
- W2039985181 creator A5038875411 @default.
- W2039985181 creator A5043134796 @default.
- W2039985181 creator A5066044016 @default.
- W2039985181 creator A5087699203 @default.
- W2039985181 date "2008-09-01" @default.
- W2039985181 modified "2023-10-17" @default.
- W2039985181 title "Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial" @default.
- W2039985181 cites W1550111394 @default.
- W2039985181 cites W1971543621 @default.
- W2039985181 cites W1982822810 @default.
- W2039985181 cites W1999818473 @default.
- W2039985181 cites W2017813663 @default.
- W2039985181 cites W2020811647 @default.
- W2039985181 cites W2021232559 @default.
- W2039985181 cites W2023943834 @default.
- W2039985181 cites W2028754099 @default.
- W2039985181 cites W2038695435 @default.
- W2039985181 cites W2042984581 @default.
- W2039985181 cites W2044049836 @default.
- W2039985181 cites W2056194572 @default.
- W2039985181 cites W2061018844 @default.
- W2039985181 cites W2065876809 @default.
- W2039985181 cites W2076448163 @default.
- W2039985181 cites W2086124255 @default.
- W2039985181 cites W2090526184 @default.
- W2039985181 cites W2118094322 @default.
- W2039985181 cites W2118932957 @default.
- W2039985181 cites W2126820850 @default.
- W2039985181 cites W2127642431 @default.
- W2039985181 cites W2139335975 @default.
- W2039985181 cites W2140773214 @default.
- W2039985181 cites W2143144750 @default.
- W2039985181 cites W2145052442 @default.
- W2039985181 cites W4231620004 @default.
- W2039985181 cites W4255518427 @default.
- W2039985181 doi "https://doi.org/10.1053/j.ajkd.2008.02.297" @default.
- W2039985181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18423812" @default.
- W2039985181 hasPublicationYear "2008" @default.
- W2039985181 type Work @default.
- W2039985181 sameAs 2039985181 @default.
- W2039985181 citedByCount "98" @default.
- W2039985181 countsByYear W20399851812012 @default.
- W2039985181 countsByYear W20399851812013 @default.
- W2039985181 countsByYear W20399851812014 @default.
- W2039985181 countsByYear W20399851812015 @default.
- W2039985181 countsByYear W20399851812016 @default.
- W2039985181 countsByYear W20399851812017 @default.
- W2039985181 countsByYear W20399851812018 @default.
- W2039985181 countsByYear W20399851812019 @default.
- W2039985181 countsByYear W20399851812020 @default.
- W2039985181 countsByYear W20399851812021 @default.
- W2039985181 countsByYear W20399851812022 @default.
- W2039985181 countsByYear W20399851812023 @default.
- W2039985181 crossrefType "journal-article" @default.
- W2039985181 hasAuthorship W2039985181A5018798170 @default.
- W2039985181 hasAuthorship W2039985181A5026517026 @default.
- W2039985181 hasAuthorship W2039985181A5032030602 @default.
- W2039985181 hasAuthorship W2039985181A5038875411 @default.
- W2039985181 hasAuthorship W2039985181A5043134796 @default.
- W2039985181 hasAuthorship W2039985181A5066044016 @default.
- W2039985181 hasAuthorship W2039985181A5087699203 @default.
- W2039985181 hasConcept C126322002 @default.
- W2039985181 hasConcept C126894567 @default.
- W2039985181 hasConcept C134018914 @default.
- W2039985181 hasConcept C142724271 @default.
- W2039985181 hasConcept C159641895 @default.
- W2039985181 hasConcept C170493617 @default.
- W2039985181 hasConcept C189135053 @default.
- W2039985181 hasConcept C198710026 @default.
- W2039985181 hasConcept C204787440 @default.
- W2039985181 hasConcept C27016395 @default.
- W2039985181 hasConcept C27081682 @default.
- W2039985181 hasConcept C2776379505 @default.
- W2039985181 hasConcept C2777880890 @default.
- W2039985181 hasConcept C2778468042 @default.
- W2039985181 hasConcept C2778525890 @default.
- W2039985181 hasConcept C2778653478 @default.
- W2039985181 hasConcept C2779611605 @default.
- W2039985181 hasConcept C2779716603 @default.
- W2039985181 hasConcept C2780306776 @default.
- W2039985181 hasConcept C2780361556 @default.
- W2039985181 hasConcept C71924100 @default.
- W2039985181 hasConcept C84393581 @default.
- W2039985181 hasConcept C87813604 @default.
- W2039985181 hasConceptScore W2039985181C126322002 @default.
- W2039985181 hasConceptScore W2039985181C126894567 @default.
- W2039985181 hasConceptScore W2039985181C134018914 @default.
- W2039985181 hasConceptScore W2039985181C142724271 @default.
- W2039985181 hasConceptScore W2039985181C159641895 @default.
- W2039985181 hasConceptScore W2039985181C170493617 @default.
- W2039985181 hasConceptScore W2039985181C189135053 @default.
- W2039985181 hasConceptScore W2039985181C198710026 @default.
- W2039985181 hasConceptScore W2039985181C204787440 @default.